Thermo Fisher Scientific Human TRANCE (RANKL) Recombinant Protein

Applications

Tested Dilution

Publications

Western Blot (WB)

Assay-dependent

-

Immunohistochemistry (IHC)

Assay-dependent

-

ELISA (ELISA)

Assay-dependent

-

Functional Assay (Functional)

Assay-dependent

-

Control (Ctrl)

Assay-dependent

-

Product Specifications

Species

Human

Expression System

E. coli

Amino acid sequence

Human TRANCE recombinant protein contains 176 amino acids

Molecular weight

20 kDa

Class

Recombinant

Type

Protein

Purity

≥98% by SDS-PAGE and HPLC

Endotoxin concentration

<0.1 ng/µg

Activity

Determined by the dose-dependent ability to induce reporter gene in HT-29 NF-κB Luc reporter cells.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Purification

purified

Storage buffer

5mM sodium phosphate, pH 7.6, with 75mM NaCl

Contains

no preservative

Storage conditions

-20°C

Shipping conditions

Wet ice (domestic); Wet or Dry ice (international)

Product Specific Information

Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute sRANKL in water to a concentration of 0.1-1.0 mg/mL. Do not vortex. This solution can be stored at 2°C to 8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein, such as 0.1% BSA and store in working aliquots at -80°C to -20°C.

Storage: The lyophilized protein is stable at room temperature for 1 month, but should be kept at -20°C for long term storage. Working aliquots stored with a carrier protein are stable for at least 3 months at -80°C to -20°C. Avoid repeated freeze/thaw cycles.

Target Information

This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes, and failed to form lobulo-alveolar mammary structures during pregnancy. Two alternatively spliced transcript variants have been found.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.